Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

Lung cancer is a leading cause of death among adults. Non-small cell lung cancer (NSCLC)
accounts for∼ 85% of all lung cancer cases. For more than half of all patients diagnosis …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

The presence of somatic mutations of the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) gene in patients with advanced nonsmall cell lung cancer (NSCLC) …

A fast, sensitive, universal and accurate method for the determination of four different
tyrosine kinase inhibitors from biological material was developed using LC–MS/MS …

Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …

BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …

Introduction Recent data show that EGFR pathway and its inhibition maintain their role after
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …

Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-
mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials …

Background The preclinical experiments and studies of congener drugs show icotinib, a new
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, can specifically bind to …